Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: A review of the literature

International Journal of Women's Health

Volumn 6, Issue 1, 2014, Pages 167-175

  Nappi, Rossella E ^a   Serrani, Marco ^b   Jenen, Jeffrey T ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b BAYER PHARMA AG   (Germany)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Heavy menstrual bleeding; Hormone withdrawal associated symptoms; Quality of life

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE; ESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; LEVONORGESTREL; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; TRANEXAMIC ACID;

ABDOMINAL CRAMP; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CEREBROVASCULAR ACCIDENT; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG USE; DYSMENORRHEA; ESTROGEN ACTIVITY; ESTROGEN SYNTHESIS; FEMALE SEXUAL DYSFUNCTION; HEADACHE; HUMAN; LIBIDO DISORDER; MENORRHAGIA; MENSTRUAL MIGRAINE; MENSTRUATION; MULTIPLE CYCLE TREATMENT; ORAL CONTRACEPTION; ORAL CONTRACEPTIVE USE; OVARY POLYCYSTIC DISEASE; PELVIC PAIN; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WITHDRAWAL BLEEDING;

EID: 84929267983     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S65481     Document Type: Review

References (62)

1. Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11(1):41-47.
2. YAZ® (drospirenone/ethinyl estradiol) tablets for oral use [prescribing information]. Monteville, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2012.
3. Dianette® [summary of product characteristics]. Berlin: Bayer Pharma AG; 2013.
4. Ortho Tri-Cyclen® tablets (norgestimate/ethinyl estradiol) tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2013.
5. ESTROSTEP® Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) tablets [prescribing information]. Rockaway, NJ: Warner Chilcott Company LLC; 2009.
6. Bayer Schering Pharma AG. Diane-35. Berlin-Wedding: Bayer Schering Pharma AG; 2010. Available from: http://www.pharmaline.co.il/images/newsletterregistration/bayer/11022011/dianedr.pdf. Accessed March 20, 2014.
7. NATAZIA® (estradiol valerate and estradiol valerate/dienogest) tablets, for oral use [prescribing information]. Monteville, NJ: Bayer Health Care Pharmaceuticals, Inc.; 2013.
8. Veljković M, Veljković S. [The risk of breast cervical, endometrial and ovarian cancer in oral contraceptive users]. Med Pregl. 2010;63(9-10): 657-661. Serbian.
9. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;127(2):442-451.
10. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010;82(3):221-229.
11. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008;78(3):218-225.
12. Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function. Eur J Contracept Reprod Health Care. 2011;16(6):458-467.
13. Palacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):57-62.
14. Nelson A, Parke S, Mellinger U, Zampaglione E, Schmidt A. Efficacy and safety of a combined oral contraceptive containing estradiol valerate/dienogest: results from a clinical study conducted in North America. J Womens Health (Larchmt). 2014;23(3):204-210.
15. Fraser IS, Römer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod. 2011;26(10):2698-2708.
16. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011;117(4):777-787.
17. Jensen JT, Parke S, Mellinger U, Serrani M, Mabey RG. Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate. Eur J Contracept Reprod Health Care. 2013;18(4):274-283.
18. Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. J Womens Health (Larchmt). 2013;22(4):378-384.
19. Raps M, Rosendaal F, Ballieux B, et al. Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial. J Thromb Haemost. 2013;11(5):855-861.
20. Endrikat J, Parke S, Trummer D, Serrani M, Duijkers I, Klipping C. Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study. Contraception. 2013;87(2):227-234.
21. Blode H, Zeun S, Parke S, et al. Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. Contraception. 2012;86(4):337-344.
22. Cicinelli E, Pinto V, Quattromini P, et al. Endometrial preparation with estradiol plus dienogest (Qlaira) for office hysteroscopic polypectomy: randomized pilot study. J Minim Invasive Gynecol. 2012;19(3):356-359.
23. Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M. Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception. 2012;86(2):96-101.
24. Caruso S, Agnello C, Romano M, et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med. 2011;8(10): 2841-2850.
25. Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31(8):573-584.
26. Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D. 2011;11(2): 159-170.
27. Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2009;14(3):221-232.
28. Ahrendt HJ, Makalová D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436-444.
29. Petraglia F, Parke S, Serrani M, Mellinger U, Römer T. Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea. Int J Gynaecol Obstet. 2014;125(3):270-274.
30. Di Carlo C, Gargano V, Sparice S, Tommaselli GA, Bifulco G, Nappi C. Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study. Gynecol Endocrinol. 2013;29(12):1048-1050.
31. Macìas G, Merki-Feld GS, Parke S, Mellinger U, Serrani M. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-bli nd, active-controlled HARMONY II study. J Obstet Gynaecol. 2013;33(6):591-596.
32. Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. Int J Womens Health. 2012;4:271-278.
33. Nappi RE, Terreno E, Sances G, et al. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception. 2013;88(3):369-375.
34. Davis SR, Bitzer J, Giraldi A, et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J Sex Med. 2013;10(12): 3069-3079.
35. Nelson A, Parke S, Makalova D, Serrani M, Palacios S, Mellinger U. Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: a pooled analysis of three studies conducted in North America and Europe. Eur J Contracept Reprod Health Care. 2013;18(4):264-273.
36. Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16(4): 258-269.
37. Bifulco G, Di Spiezio Sardo A, De Rosa N, et al. The use of an oral contraceptive containing estradiol valerate and dienogest before office operative hysteroscopy: a feasibility study. Gynecol Endocrinol. 2012;28(12):949-955.
38. De Leo V, Fruzzetti F, Musacchio MC, Scolaro V, Di Sabatino A, Morgante G. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception. 2013;88(3):364-368.
39. Bitzer J, Parke S, Roemer T, Serrani M. Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest. Int J Womens Health. 2011;3:127-132.
40. Di Carlo C, Gargano V, Sparice S, et al. Short-term effects of an oral contraceptive containing oestradiol valerate and dienogest on bone metabolism and bone mineral density: an observational, preliminary study. Eur J Contracept Reprod Health Care. 2013;18(5):388-393.
41. Mueck AO, Seeger H, Bühling KJ. Why use of dienogest for the first contraceptive pill with estradiol? Gynecol Endocrinol. 2010;26(2):109-113.
42. Mueck AO. Dinogest: an oral progestogen for the treatment of endometriosis. Expert Rev Obstet Gynecol. 2011;6(1):5-15.
43. Lefebvre G, Pinsonneault O, Antao V, et al; SOGC. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can. 2005;27(12): 1117-1146.
44. Hallberg L, Högdahl AM, Nilsson L, Rybo G. Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45(3):320-351.
45. Munro MG, Critchley HO, Broder MS, Fraser IS;FIGO Working Group on Menstrual Disorders FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13.
46. Hallberg L, Nilsson L. Determination of menstrual blood loss. Scand J Clin Lab Invest. 1964;16:244-248.
47. Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(3):625-632
48. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990;97(8): 690-694.
49. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG. 2005;112(8):1121-1125.
50. Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception. 1995;51(4):231-235.
51. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95(2):261-266.
52. Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007;47(1):27-37.
53. Bitzer J. Hormone withdrawal-associated symptoms: overlooked and under-explored. Gynecol Endocrinol. 2013;29(6):530-535.
54. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. Geneva: World Health Organization; 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf. Accessed January 22, 2014.
55. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use 2010. MMWR. 2010;59:1-86.
56. Edlow AG, Bartz D. Hormonal contraceptive options for women with headache: a review of the evidence. Rev Obstet Gynecol. 2010;3(2):55-65.
57. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2006;12(2):169-178.
58. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164(3):879-883.
59. Xiao B, Wu SC, Chong J, Zeng T, Han LH, Luukkainen T. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003;79(4):963-969.
60. Shaaban MM, Shabaan MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011;83(1):48-54.
61. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):865-875.
62. Center for Drug Evaluation and Research. Application number: 22-252, Original 1. Statistical Review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022252_Orig-1_StatR.pdf. U.S. Department of Health and Human Services, Food and Drug Administration; 2010. Accessed July 7, 2014.